Immunomodulatory News and Research

RSS

Co-infection reduces severity of East Coast fever, can help curb human malaria

When calves are infected by two parasite species at the same time, one parasite renders the other far less deadly, according to a new study published in the current journal of Science Advances.

24 Mar 2015

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.

20 Jan 2015

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Alzheimer's disease report success in harnessing mouse's immune system to attack toxic proteins

Alzheimer's disease experts at NYU Langone Medical Center and elsewhere are reporting success in specifically harnessing a mouse's immune system to attack and remove the buildup of toxic proteins in the brain that are markers of the deadly neurodegenerative disease.

9 Sep 2014

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus.

12 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

Inflammatory shift in long-standing bipolar disorder

Patients with chronic bipolar disorder, but not those with schizophrenia, have a shift towards an M1 rather than an M2 macrophage response, research suggests.

15 Jul 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

Perelman School wins $10M renewal to study oldest part of human immune system

The National Institute of Allergy and Infectious Diseases has awarded the Perelman School of Medicine at the University of Pennsylvania a five-year, $10 million renewal of a program project to study the oldest part of the human immune system called the complement system, or simply "complement."

30 May 2014

TCM announces winners of 26th Annual Industry Awards

The Tech Council of Maryland (TCM), Maryland's largest technology trade association for life science and technology, today announced the winners of its 26th Annual Industry Awards.

16 May 2014

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer.

15 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

$Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM$

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM).

28 Mar 2014

Simvastatin may slow progression of multiple sclerosis

Results of a phase 2 study published in The Lancet suggest that simvastatin, a cheap cholesterol lowering drug, might be a potential treatment option for the secondary progressive, or chronic, stage of multiple sclerosis (MS), which is currently untreatable.

20 Mar 2014

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

3 Feb 2014

Co-culture with mesenchymal stem cells results in improved viability, function of human hepatocytes

Hepatocyte transplantation is becoming an accepted therapy for acute liver failure, either for liver regeneration or as a bridge to liver transplantation. However, maintaining the viability and functional aspects of hepatocytes has been a concern even with successful freezing.

19 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013